Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Result s: Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
Citations
Citations to this article as recorded by
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study Qi Feng, Pinelopi Manousou, Chioma N. Izzi-Engbeaya, Mark Woodward Cardiovascular Diabetology.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Alcohol Intake and Cardiometabolic Risk Factors Are Independently Associated With a Higher AST/Platelet Ratio Index in Obese Males Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Tsubasa Tsutsumi, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nakajima, Tomoari Kam Liver International Communications.2025;[Epub] CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez PLOS One.2025; 20(7): e0327772. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators Yoshihiro Kamada, Takunori Sato, Takaomi Kessoku, Yoshio Sumida, Masafumi Ono, Kenji Ryotokuji Laser Therapy.2025;[Epub] CrossRef
Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders Yoshihiro Kamada, Makoto Fujii, Hitoshi Nishizawa, Shiro Fukuda, Makoto Yamada, Iichiro Shimomura, Eiji Miyoshi Hepatology Research.2025;[Epub] CrossRef
Concept, Diagnosis, and Treatment in Steatotic Liver Disease (SLD) Yoshio Sumida, Takaomi Kessoku, Hirotoshi Ebinuma Health Evaluation and Promotion.2025; 52(6): 794. CrossRef
COMBINED DISORDER: CURRENT STATUS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH HYPOTHYROIDISM AND PROSPECTS FOR PATIENT PATHWAY IMPLEMENTATION Valentyna Psarova, Anastasiia Cherkashyna Eastern Ukrainian Medical Journal.2025; 13(3): 593. CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Yeo-Wool Kang, Yang-Hyun Baek, Sang-Yi Moon Diagnostics.2024; 14(22): 2517. CrossRef
Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim Gut and Liver.2024; 18(6): 1048. CrossRef
First
Prev
